Motley Fool  Jan 21  Comment 
MannKind partner Sanofi is close to launching its inhaled insulin Afrezza, but will doctors prescribe it?
Motley Fool  Jan 13  Comment 
Alfred Mann retires as CEO, but investors needn't worry.
Benzinga  Jan 12  Comment 
Speaking to Benzinga, Griffin Securities Analyst Dr. Keith Markey said that after MannKind Corporation (NASDAQ: MNKD) founder Alfred Mann retires from his role as CEO, the new management will probably not pursue a merger with Sanofi SA (ADR)...
TheStreet.com  Jan 12  Comment 
Updated with additional information from 1:35 pm EST SAN FRANCISCO ( TheStreet) -- MannKind CEO Al Mann is retiring and the company's inhaled insulin device Afrezza still has no publicly disclosed commercial launch date.  Elias...
Wall Street Journal  Jan 12  Comment 
MannKind Corp. said Monday that its board appointed Hakan Edstrom chief executive officer as founder Alfred Mann stepped aside to become executive chairman.
Motley Fool  Jan 9  Comment 
Afrezza could be a game-changing inhaled diabetes therapy, but it must overcome an obstacle that crushed previous potential game changers.
Motley Fool  Jan 8  Comment 
Sanofi has made a $50 million milestone payment to MannKind, but Afrezza's success or failure is far more important to MannKind this year.


MannKind is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diabetes, cancer, and inflammatory and autoimmune diseases. The company's lead product, the Technosphere Insulin System, meant for the treatment of diabetes, is in a series of pivotal phase III trial in the U.S. This product utilizes MannKind s proprietary dry powder Technosphere formulation of insulin. It is inhaled deep into the lungs using the company s MedTone inhaler. Besides the company s development of Technosphere, MannKind is pursuing efforts aimed at the discovery and development of novel drugs for metabolic and immunological diseases. The company also has early-stage development programs for the treatment of solid-tumor cancers. MannKind initiated phase I trials with its cancer candidates in early 2007. MannKind's corporate headquarters and immunology research operations are located in Valencia, CA. Significant operations, including the Technosphere Insulin research, development and manufacturing are located in Danbury, CT. The company's initial public offering (IPO) took place in late July 2004.

Business & Financial Metrics[1]

In 2009, MannKind incurred a net loss of $220.1 million and reported no revenue. This represents a 27.4% reduction in net loss from 2008, when the company lost $303.0 million. Since its inception in 1991, MannKind has lost $1.60 billion and generated $3.0 million in revenues.


MannKind's primary competitors include:


  1. MNKD 2009 10-K pg. 64  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki